Rafiq Hasan
CEO
Complement Therapeutics
Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Raised to date
$78.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Geographic Atrophy, the late stage of dry age‑related macular degeneration, causes irreversible vision loss and currently has no approved therapy. Similar complement‑mediated mechanisms also drive a range of systemic diseases, creating unmet clinical needs across ophthalmology and other specialties.
Solution
Complement Therapeutics leverages deep expertise in complement biology to develop novel therapeutics that modulate the complement cascade. Its lead program, CTx001, is an AAV‑based gene therapy designed to correct complement dysregulation in the retina and halt progression of Geographic Atrophy. The company also pursues protein‑based approaches for systemic complement‑mediated conditions. In parallel, it operates a Complement Precision Medicine (CPM) platform that quantifies multiple complement proteins from a single blood draw, enabling patient stratification and disease monitoring for clinical trials and future commercial use.
Target Audience
Primary customers are ophthalmology and retinal specialists conducting clinical trials for Geographic Atrophy, as well as pharmaceutical partners developing therapies for systemic complement‑mediated diseases such as chronic kidney disorders, multiple sclerosis, and Alzheimer’s disease.
Features
- AAV gene‑therapy (CTx001) targeting multiple complement pathways to treat Geographic Atrophy in a single administration
- Protein‑based therapeutic candidates aimed at systemic complement dysregulation (e.g., renal and neurological diseases)
- Complement Precision Medicine platform using mass spectrometry to measure an array of complement proteins, including C3, Factor I, Factor H, and the FHR family, from one blood sample
- Platform‑validated in healthy donors and disease cohorts, supporting patient selection and biomarker‑driven trial design
- Proprietary insights into factor‑H‑related proteins (FHRs) that inform mechanism of action and target selection